

I HEREBY CERTIFY THAT THIS COMMUNICATION IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, DC, 20231 ON THE DATE APPEARING BELOW.

AHP-9897-6-N5
PATENT



Aug 17, 1995
5661
0380 8/31

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: R. E. Morris
C. R. Gregory

Serial No.: 08/452,051

Examiner:

Filed: May 26, 1995

Group: 1808

For: Method of Treating Hyperproliferative
Vascular Disease

Assistant Commissioner for Patents
Washington, DC 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97(b)(1)

Sir:

Transmitted herewith is an Information Disclosure Statement for the above identified application that is being mailed within three months of the filing date of May 26, 1995. No fee is due.

The Commissioner is hereby authorized to charge any additional fee due as required under 37 C.F.R 1.17(p) by this paper to Deposit Account No. 01-1425. Two additional copies of this sheet are enclosed.

Respectfully submitted,


Arnold S. Milowsky
Reg. No. 35,288

Dated: August 17, 1995
Telephone: (610) 902-2635

I HEREBY CERTIFY THAT THIS COMMUNICATION IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, DC, 20231, ON THE DATE APPEARING BELOW.

1808
AHP-9897-6-N5
PATENT



DATE

Angela Kargi
August 17, 1995

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: R.E. Morris
C.R. Gregory

Serial No.: 08/452,051

Examiner:

Filed: May 26, 1995

Group: 1808

For: Method of Treating Hyperproliferative Vascular Disease

Assistant Commissioner for Patents
Washington, DC 20231

*1808
1-0096*

INFORMATION DISCLOSURE STATEMENT UNDER RULE 97(b)(1)

Sir:

With respect to the subject matter of the above-identified application, the applicant is aware of the following references, which may have relevance to the examination of the invention claimed. These references were cited by the applicants or cited by the Examiner in U.S.S.N. 08/238,305 U.S.S.N. 07/980,000, or U.S.S.N. 07/819,314 from which priority under 35 U.S.C. 120 are claimed. Copies of these references are not enclosed pursuant to 37 C.F.R. 1.98(d).

American Society of Transplant Physicians, 13th Annual Meeting, May 16-18, 1994;

Abstract (38) 9, mailed to attendees April 27, 1994

American Society of Transplant Physicians, 13th Annual Meeting, May 16-18, 1994;

Abstract (38) 10, mailed to attendees April 27, 1994

Transplantation Proc. 25: 120 (1993)

Transplantation Proc. 25: 770 (1993)

Transplantation 55: 1409 (1993)

Veterinary Surgery, 11 Abstract 40 (1993)

J. Heart Lung Transplant 11: 197 (Abs 27) (1992)

FASEB 6: A940 (Abs 21) (1992)

U.S. Patent 5,100,899


J. Heart Lung Transplant. 9: 55 (1990)

Lancet 338: 1297 (1991)

Circulation 80 (Supp. II): 183 (1989)

Proc. Natl. Acad. Sci. 85: 2303 (1988)
U.S. Patent 3,929,992
Transplantation Reviews 6: 39 (1992)
FASEB 3,3411 (1989)
Can. J. Physiol. Pharmacol. 55, 48 (1977)
Med. Sci. Res. 17: 877 (1989)
European Patent Application 0401747 A2
U.S. Patent 5,078,999
U.S. Patent 5,080,899
Abstract: Fifth Int. Conf. of Inflammation Research Association 121, September 23, 1990
J. Antibiotics 37: 1231 (1984)
U.S. Patent Application S.N. 07/717,773 (filed 6/18/91)
U.S. Patent 4,885,171
The Merck Index, Ed. pp. 820-821, No. 6152 (1976)
J. Cell Biol 111: Abstract 1308, p. 234a
Transplantation Proc. 23: 2833 (1991)
Cytokine 3: 472 (1991)
Transplantation Proc. 23: 507 (1991)
Transplantation 50: 554 (1990)
Immunology 72: 544 (1991)
Ferns, G., Am. J. Path. 137: 403 (1990)
U.S. Patent 5,288,711
U.S. Patent 5,256,790
U.S. Patent 5,252,579

Respectfully submitted,


Arnold S. Mijowsky
Reg. No. 35,288

Dated: August 17, 1995
Telephone: (610) 902-2635